tradingkey.logo
tradingkey.logo
Suchen

Beta Bionics Inc

BBNX
Zur Watchlist hinzufügen
16.760USD
+0.060+0.36%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
746.85MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Beta Bionics Inc Unternehmen

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

Beta Bionics Inc Informationen

BörsenkürzelBBNX
Name des UnternehmensBeta Bionics Inc
IPO-datumJan 30, 2025
CEOSaint (Sean)
Anzahl der mitarbeiter291
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse11 Hughes
StadtIRVINE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92618
Telefon19494277785
Websitehttps://www.betabionics.com
BörsenkürzelBBNX
IPO-datumJan 30, 2025
CEOSaint (Sean)

Führungskräfte von Beta Bionics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%
Mr. Adam Lezack
Mr. Adam Lezack
Independent Chairman of the Board
Independent Chairman of the Board
23.40K
+63.96%
Mr. Sean Saint
Mr. Sean Saint
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.67K
-297.67%
Mr. Stephen Feider
Mr. Stephen Feider
Chief Financial Officer
Chief Financial Officer
3.18K
-210.20%
Mr. Michael (Mike) Mensinger
Mr. Michael (Mike) Mensinger
Chief Product Officer
Chief Product Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steven Russell, M.D., Ph.D.
Dr. Steven Russell, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
173.85K
-2.43%
Mr. Mark Hopman
Mr. Mark Hopman
Chief Commercial Officer
Chief Commercial Officer
95.61K
-5.86%
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Independent Director
Independent Director
29.51K
+57.49%
Mr. Sean D. Carney
Mr. Sean D. Carney
Independent Director
Independent Director
28.21K
+60.13%
Dr. Maria Palasis, Ph.D.
Dr. Maria Palasis, Ph.D.
Independent Director
Independent Director
25.40K
+66.79%
Ms. Christy Jones
Ms. Christy Jones
Independent Director
Independent Director
23.40K
-12.01%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Beta Bionics Inc?

Die fünf größten Anteilseigner von Beta Bionics Inc sind: Dr. Steven Russell, M.D., Ph.D.

Wie viele Institutionen halten Anteile an Beta Bionics Inc (BBNX)?

Mit Stand vom 2026Q1 halten 264 Institutionen Anteile an Beta Bionics Inc, mit einem Gesamtmarktwert von etwa 49.25M, was 110.51% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2186348.00 gestiegen.

Was ist die größte Einnahmequelle von Beta Bionics Inc?

Am 2026Q1 erzielte das Geschäft mit DME channel - iLet für Beta Bionics Inc den höchsten Umsatz in Höhe von 52.05M, was 51.92% des Gesamtumsatzes entspricht.